{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T16:57:07Z","timestamp":1767373027362,"version":"3.40.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"DOI":"10.7759\/cureus.83751","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:01:02Z","timestamp":1746748862000},"source":"Crossref","is-referenced-by-count":1,"title":["Carcinoembryonic Antigen (CEA) Elevation in Routine Screening Unveils Stage IV Lung Adenocarcinoma"],"prefix":"10.7759","author":[{"given":"Farha Munira","family":"Mohamed Kamel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor Azimah","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Zharif","family":"Adenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3393\/ac.2019.11.13","article-title":"A review of the role of carcinoembryonic antigen in clinical practice","volume":"35","author":"Hall C","year":"2019","unstructured":"Hall C, Clarke L, Pal A, Buchwald P, Eglinton T, Wakeman C, Frizelle F. A review of the role of carcinoembryonic antigen in clinical practice. Ann Coloproctol. 2019, 35:294-305. 10.3393\/ac.2019.11.13","journal-title":"Ann Coloproctol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00410109","article-title":"CEA (carcinoembryonic antigen): its role as a marker in the management of cancer","volume":"101","author":"Goldenberg DM","year":"1981","unstructured":"Goldenberg DM, Neville AM, Carter AC, et al.. CEA (carcinoembryonic antigen): its role as a marker in the management of cancer. J Cancer Res Clin Oncol. 1981, 101:239-42. 10.1007\/BF00410109","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.11.012","article-title":"Carcinoembryonic antigen (CEA) as tumor marker in lung cancer","volume":"76","author":"Grunnet M","year":"2012","unstructured":"Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012, 76:138-43. 10.1016\/j.lungcan.2011.11.012","journal-title":"Lung Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.14715\/CMB\/2017.64.15.11","article-title":"Combined detection of CEA and CA125 for the diagnosis for lung cancer: a meta-analysis","volume":"64","author":"Wu LX","year":"2018","unstructured":"Wu LX, Li XF, Chen HF, et al.. Combined detection of CEA and CA125 for the diagnosis for lung cancer: a meta-analysis. Cell Mol Biol. 2018, 64:67-70. 10.14715\/CMB\/2017.64.15.11","journal-title":"Cell Mol Biol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5455\/njppp.2023.13.06302202324072023","article-title":"A clinicopathological study of the correlation of level of carcinoembryonic antigen in colorectal carcinoma in a tertiary care medical college in Eastern India","volume":"14","author":"Nath S","year":"2023","unstructured":"Nath S, Karmakar S, Ranjan S. A clinicopathological study of the correlation of level of carcinoembryonic antigen in colorectal carcinoma in a tertiary care medical college in Eastern India. Natl J Physiol Pharm Pharmacol. 2023, 14:329-33. 10.5455\/njppp.2023.13.06302202324072023","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.3038","article-title":"A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1) and early-stage NSC lung cancer detection","volume":"41","author":"Tcherkassova J","year":"2023","unstructured":"Tcherkassova J, Tsurkan S, Prostyakova A, et al.. A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1) and early-stage NSC lung cancer detection. J Clin Oncol. 2023, 41:3038. 10.1200\/jco.2023.41.16_suppl.3038","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01483-x","article-title":"CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies","volume":"125","author":"Moretto R","year":"2021","unstructured":"Moretto R, Rossini D, Conca V, et al.. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. Br J Cancer. 2021, 125:839-45. 10.1038\/s41416-021-01483-x","journal-title":"Br J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.16899\/JCM.840949","article-title":"Evaluating lung cancer with tumor markers: CEA, CA 19-9 and CA 125","volume":"11","author":"Ayd\u0131n S","year":"2021","unstructured":"Ayd\u0131n S, Balc\u0131 A, Emin M. Evaluating lung cancer with tumor markers: CEA, CA 19-9 and CA 125. J Contemp Med. 2021, 11:282-7. 10.16899\/JCM.840949","journal-title":"J Contemp Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000074432","article-title":"Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors","volume":"24","author":"Molina R","year":"2003","unstructured":"Molina R, Filella X, Aug\u00e9 JM, et al.. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 2003, 24:209-18. 10.1159\/000074432","journal-title":"Tumour Biol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/147323000903700219","article-title":"The efficacy of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in determining the malignancy of solitary pulmonary nodules","volume":"37","author":"Bekci TT","year":"2009","unstructured":"Bekci TT, Senol T, Maden E. The efficacy of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in determining the malignancy of solitary pulmonary nodules. J Int Med Res. 2009, 37:438-45. 10.1177\/147323000903700219","journal-title":"J Int Med Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3564438","article-title":"Role of serum tumor biomarkers in evaluating lung cancer","author":"Khan R","year":"2020","unstructured":"Khan R, Javed A, Kumar V. Role of serum tumor biomarkers in evaluating lung cancer. Lancet. 2020, 2020. 10.2139\/ssrn.3564438","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2082840","article-title":"Identifying the best marker combination in CEA, CA125, CY211, NSE, and SCC for lung cancer screening by combining ROC curve and logistic regression analyses: is it feasible?","volume":"2018","author":"Yang Q","year":"2018","unstructured":"Yang Q, Zhang P, Wu R, Lu K, Zhou H. Identifying the best marker combination in CEA, CA125, CY211, NSE, and SCC for lung cancer screening by combining ROC curve and logistic regression analyses: is it feasible?. Dis Markers. 2018, 2018:2082840. 10.1155\/2018\/2082840","journal-title":"Dis Markers"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.36497\/respirsci.v4i3.142","article-title":"Carcinoembryonic antigen (CEA) and cancer antigen 125 (CA-125) as diagnostic biomarkers for malignant pleural effusion","volume":"4","author":"Harsini H","year":"2024","unstructured":"Harsini H, Kurniawan YD, Sutanto Y. Carcinoembryonic antigen (CEA) and cancer antigen 125 (CA-125) as diagnostic biomarkers for malignant pleural effusion. Respir Sci. 2024, 4:164-71. 10.36497\/respirsci.v4i3.142","journal-title":"Respir Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/03936155231158661","article-title":"Pleural CEA, CA-15-3, CYFRA 21-1, CA-19-9, CA-125 discriminating malignant from benign pleural effusions: diagnostic cancer biomarkers","volume":"38","author":"Fazli Khalaf F","year":"2023","unstructured":"Fazli Khalaf F, Asadi Gharabaghi M, Balibegloo M, Davari H, Afshar S, Jahanbin B. Pleural CEA, CA-15-3, CYFRA 21-1, CA-19-9, CA-125 discriminating malignant from benign pleural effusions: diagnostic cancer biomarkers. Int J Biol Markers. 2023, 38:81-8. 10.1177\/03936155231158661","journal-title":"Int J Biol Markers"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.1093","article-title":"Evaluation of comparative surveillance strategies of circulating tumor DNA, imaging, and carcinoembryonic antigen levels in patients with resected colorectal cancer","volume":"5","author":"Fakih M","year":"2022","unstructured":"Fakih M, Sandhu J, Wang C, et al.. Evaluation of comparative surveillance strategies of circulating tumor DNA, imaging, and carcinoembryonic antigen levels in patients with resected colorectal cancer. JAMA Netw Open. 2022, 5:221093. 10.1001\/jamanetworkopen.2022.1093","journal-title":"JAMA Netw Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.23736\/S0026-4806.21.07124-X","article-title":"Comparison of serum tumor markers combined with dual-source CT in the diagnosis of lung cancer","volume":"114","author":"Shan Y","year":"2023","unstructured":"Shan Y, Yin X, Zhao N, Wang J, Yang S. Comparison of serum tumor markers combined with dual-source CT in the diagnosis of lung cancer. Minerva Med. 2023, 114:795-801. 10.23736\/S0026-4806.21.07124-X","journal-title":"Minerva Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000001138","article-title":"Meta-analysis of targeted therapies in EGFR-mutated non-small cell lung cancer: efficacy and safety of osimertinib, erlotinib, and gefitinib as first-line treatment","volume":"48","author":"Qureshi Z","year":"2025","unstructured":"Qureshi Z, Altaf F, Jamil A, Siddique R. Meta-analysis of targeted therapies in EGFR-mutated non-small cell lung cancer: efficacy and safety of osimertinib, erlotinib, and gefitinib as first-line treatment. Am J Clin Oncol. 2025, 48:44-54. 10.1097\/COC.0000000000001138","journal-title":"Am J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/361714-carcinoembryonic-antigen-cea-elevation-in-routine-screening-unveils-stage-iv-lung-adenocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:01:02Z","timestamp":1746748862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/361714-carcinoembryonic-antigen-cea-elevation-in-routine-screening-unveils-stage-iv-lung-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.83751","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,8]]}}}